Payment overview · 2025
General Payments
$1,929.68
87 reported records · 25 companies
Healthcare provider profile · identity verified
David A. Dicecco, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NORTH PROVIDENCE, RI · NPI 1831201839
Verified facts
What the public records show
CMS Open Payments records show David A. Dicecco, M.D. received $1,929.68 in general payments during 2025 across 87 reported records.
Grifols USA, LLC accounted for 15.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $298.95 | 15.5% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $166.97 | 8.7% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.65 | 8.2% | 6 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $152.09 | 7.9% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $119.73 | 6.2% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $111.97 | 5.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $98.95 | 5.1% | 5 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $93.33 | 4.8% | 4 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $83.55 | 4.3% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.94 | 4.2% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $70.45 | 3.6% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.36 | 3.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.47 | 3.3% | 3 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $56.37 | 2.9% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $52.61 | 2.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.07 | 2.2% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $41.09 | 2.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $26.31 | 1.4% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $25.97 | 1.4% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $24.54 | 1.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.91 | 1.2% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $19.63 | 1.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.77 | 1.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.49 | 1.0% | 1 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $13.51 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,929.68 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $298.95 | 13 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $158.65 | 6 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $152.09 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $151.39 | 7 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $139.70 | 6 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $119.73 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $111.97 | 5 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $93.33 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $84.72 | 4 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $83.55 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $66.36 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $56.37 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $52.61 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.07 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.95 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $26.17 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $25.97 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 855 | 209 |
| Amlodipine Besylate | Amlodipine Besylate | 600 | 128 |
| Eliquis | Apixaban | 435 | 47 |
| Trazodone Hcl | Trazodone Hcl | 424 | 84 |
| Furosemide | Furosemide | 419 | 60 |
| Lisinopril | Lisinopril | 391 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 62 |
| Omeprazole | Omeprazole | 331 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 64 |
| Gabapentin | Gabapentin | 262 | 51 |
| Metformin Hcl | Metformin Hcl | 247 | 56 |
| Meloxicam | Meloxicam | 220 | 46 |
| Sertraline Hcl | Sertraline Hcl | 214 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 213 | 78 |
| Losartan Potassium | Losartan Potassium | 203 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 44 |
| Mirtazapine | Mirtazapine | 183 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 166 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 42 |
| Xarelto | Rivaroxaban | 149 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 38 |
| Ezetimibe | Ezetimibe | 133 | 31 |
| Azithromycin | Azithromycin | 128 | 81 |
| Simvastatin | Simvastatin | 127 | 27 |
| Potassium Chloride | Potassium Chloride | 118 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 26 |
| Ibuprofen | Ibuprofen | 106 | 21 |
| Jardiance | Empagliflozin | 99 | 13 |
| Donepezil Hcl | Donepezil Hcl | 90 | 22 |
| Atenolol | Atenolol | 89 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 16 |
| Risperidone | Risperidone | 76 | suppressed |
| Glimepiride | Glimepiride | 75 | 21 |
| Famotidine | Famotidine | 73 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 12 |
| Spironolactone | Spironolactone | 69 | 13 |
| Lorazepam | Lorazepam | 67 | 15 |
| Alprazolam | Alprazolam | 64 | 12 |
| Valsartan | Valsartan | 62 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 13 |
| Clonazepam | Clonazepam | 59 | suppressed |
| Allopurinol | Allopurinol | 54 | 11 |
| Latanoprost | Latanoprost | 54 | suppressed |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 53 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | suppressed |
| Bumetanide | Bumetanide | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 12 |
| Alendronate Sodium | Alendronate Sodium | 48 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 24 |
| Finasteride | Finasteride | 48 | 11 |
| Meclizine Hcl | Meclizine Hcl | 48 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Carvedilol | Carvedilol | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 13 |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 26 |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Lactulose | Lactulose | 42 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 40 | 12 |
| Cephalexin | Cephalexin | 37 | 23 |
| Prednisone | Prednisone | 36 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 23 |
| Spiriva Respimat | Tiotropium Bromide | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Klor-Con 10 | Potassium Chloride | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Nadolol | Nadolol | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | suppressed |
| Erythromycin | Erythromycin Base | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,929.68 · 87 records | Grifols USA, LLC | ACTHAR, AMVUTTRA, AREXVY, Arikayce, Cologuard Collection Kit, DOVATO, DUPIXENT, FARXIGA, FASENRA, FREESTYLE LIBRE 3, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, LUNA, NUZYRA, OFEV, OPSUMIT, Ohtuvayre, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, REXULTI, SHINGRIX, Sunosi, TELEPATCH CARDIAC MONITOR, TEZSPIRE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UPTRAVI, Vest Therapy Und, ZERBAXA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error